AngioDynamics Announces First Patient Enrolled in PICC Related Obstruction of Flow (PROOF) Study

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALBANY, N.Y., Oct. 3, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced the enrollment of the first patient at University of Miami Hospital in a randomized multi-center study investigating whether the BioFlo PICC will be associated with a reduced incidence of catheter-related venous thrombosis, including both symptomatic and asymptomatic, compared to another commercially available PICC, the Bard PowerPICC SOLO2.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC